Armin Mooranian1, Rebecca Negrulj1, Hani Al-Salami2. 1. Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia. 2. Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia. hani.al-salami@curtin.edu.au.
Abstract
PURPOSE: The encapsulation of pancreatic β-cells in biocompatible matrix has generated great interest in diabetes treatment. Our work has shown improved microcapsules when incorporating the bile acid ursodeoxycholic acid (UDCA), in terms of morphology and cell viability although cell survival remained low. Thus, the study aimed at incorporating the polyelectrolytes polyallylamine (PAA) and poly-l-ornithine (PLO), with the polymer sodium alginate (SA) and the hydrogel ultrasonic gel (USG) with UDCA and examined cell viability and functionality post microencapsulation. METHODS: Microcapsules without (control) and with UDCA (test) were produced using 1% PLO, 2.5% PAA, 1.8% SA and 4.5% USG. Pancreatic β-cells were microencapsulated and the microcapsules' morphology, surface components, cellular and bile acid distribution, osmotic and mechanical stability as well as biocompatibilities, insulin production, bioenergetics and the inflammatory response were tested. RESULTS: Incorporation of UDCA at 4% into a PLO-PAA-SA formulation system increased cell survival (p < 0.01), insulin production (p < 0.01), reduced the inflammatory profile (TNF-α, IFN-ϒ, IL-6 and IL-1β; p < 0.01) and improved the microcapsule physical and mechanical strength (p < 0.01). CONCLUSIONS: β-cell microencapsulation using 1% PLO, 2.5% PAA, 1.8% SA, 4.5% USG and the bile acid UDCA (4%) has good potential in cell transplantation and diabetes treatment.
PURPOSE: The encapsulation of pancreatic β-cells in biocompatible matrix has generated great interest in diabetes treatment. Our work has shown improved microcapsules when incorporating the bile acid ursodeoxycholic acid (UDCA), in terms of morphology and cell viability although cell survival remained low. Thus, the study aimed at incorporating the polyelectrolytes polyallylamine (PAA) and poly-l-ornithine (PLO), with the polymer sodium alginate (SA) and the hydrogel ultrasonic gel (USG) with UDCA and examined cell viability and functionality post microencapsulation. METHODS: Microcapsules without (control) and with UDCA (test) were produced using 1% PLO, 2.5% PAA, 1.8% SA and 4.5% USG. Pancreatic β-cells were microencapsulated and the microcapsules' morphology, surface components, cellular and bile acid distribution, osmotic and mechanical stability as well as biocompatibilities, insulin production, bioenergetics and the inflammatory response were tested. RESULTS: Incorporation of UDCA at 4% into a PLO-PAA-SA formulation system increased cell survival (p < 0.01), insulin production (p < 0.01), reduced the inflammatory profile (TNF-α, IFN-ϒ, IL-6 and IL-1β; p < 0.01) and improved the microcapsule physical and mechanical strength (p < 0.01). CONCLUSIONS: β-cell microencapsulation using 1% PLO, 2.5% PAA, 1.8% SA, 4.5% USG and the bile acid UDCA (4%) has good potential in cell transplantation and diabetes treatment.
Authors: Marc Y Donath; Jan A Ehses; Kathrin Maedler; Desiree M Schumann; Helga Ellingsgaard; Elisabeth Eppler; Manfred Reinecke Journal: Diabetes Date: 2005-12 Impact factor: 9.461
Authors: Joana D Amaral; Ricardo J S Viana; Rita M Ramalho; Clifford J Steer; Cecília M P Rodrigues Journal: J Lipid Res Date: 2009-05-05 Impact factor: 5.922
Authors: X Zheng; X Zheng; X Wang; Z Ma; V Gupta Sunkari; I Botusan; T Takeda; A Björklund; M Inoue; S-B Catrina; K Brismar; L Poellinger; T S Pereira Journal: Cell Death Dis Date: 2012-06-14 Impact factor: 8.469
Authors: Armin Mooranian; Thomas Foster; Corina M Ionescu; Louise Carey; Daniel Walker; Melissa Jones; Susbin Raj Wagle; Bozica Kovacevic; Jacqueline Chester; Edan Johnstone; Jafri Kuthubutheen; Daniel Brown; Marcus D Atlas; Momir Mikov; Hani Al-Salami Journal: Drug Des Devel Ther Date: 2021-10-23 Impact factor: 4.162